PTC Therapeutics (PTCT) Reports Q4 Loss, Lags Revenue Estimates

Core Insights - PTC Therapeutics reported a quarterly loss of $0.24 per share, significantly better than the Zacks Consensus Estimate of a loss of$0.96, representing a 75% earnings surprise [1] - The company generated revenues of $213.17 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 3.96$307.06 million year-over-year [2] - PTC Therapeutics has outperformed the S&P 500 with a 12.9% increase in share price since the beginning of the year [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$1.22 on revenues of$168.72 million, and for the current fiscal year, it is -$4.49 on revenues of$738.12 million [7] - The estimate revisions trend for PTC Therapeutics is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which PTC Therapeutics belongs, is currently in the top 28% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, Zymeworks Inc., is expected to report a quarterly loss of $0.32 per share, reflecting a year-over-year change of -60$36.74 million, up 117% from the previous year [9][10]